- 研究领域
- 技术
- 仪器平台
- 试剂和服务
- 生物信息学
- 科学内容
- ILLUMINA公司
- 支持
TruSight Tumor 170, a next-generation sequencing assay designed to cover 170 genes associated with common solid tumors, is an enrichment-based targeted panel that simultaneously analyzes DNA and RNA, covering a wide range of genes and variant types. The comprehensive nature provides laboratories with a deep view into the genetics of cancer.
Results of analysis indicate that TruSight Tumor 170, with comprehensive coverage of cancer-related genes, shows high concordance with whole exome sequencing for accurate assessment of tumor mutational burden.
Standard extractions from FFPE embedded samples provide sufficient material (40ng) in >95% of samples that were extracted by Illumina. This data shows that the TruSight Tumor 170 panel is a robust assay that generates passing sample QC data in >85% of samples with varying quality, and in >95% of samples that have quality metrics that fall within the recommendations for the kit.
TruSight Tumor 170 can achieve high sensitivity and specificity for the detection of somatic variants (small variants and CNVs) from DNA extracted from FFPE tissues.
Through examining limit of detection in the context of RNA expression, this study shows that TruSight Tumor 170 provides high sensitivity and specificity in RNA variant calling down to 5 copies of transcript per ng of input.
Error Rate Reduction with the TruSight Oncology UMI Reagents for Variant Detection
Technical Note | PDF < 1 MB
Application Note | PDF 2 MB
Assessing DNA and RNA Quality from FFPE Samples for TruSight Tumor 170
White Paper | PDF < 1 MB
Data Sheet | PDF < 1 MB
product_file | EXCEL < 1 MB
癌症Panel TruSight RNA Fusion Panel靶向RNA测序集合是一项高性价比的解决方案，可检出多种癌症中的基因融合,且该癌症Panel具有识别新融合基因伙伴的功能。
